Vera Therapeutics’ (VERA) Buy Rating Reiterated at HC Wainwright

Vera Therapeutics (NASDAQ:VERA)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Monday, Marketbeat reports. They currently have a $85.00 price objective on the stock, up from their previous price objective of $75.00. HC Wainwright’s price objective suggests a potential upside of 286.77% from the company’s current price. HC Wainwright also issued estimates for Vera Therapeutics’ Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.44) EPS, Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.79) EPS, Q3 2026 earnings at ($0.84) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($2.64) EPS, FY2027 earnings at $1.03 EPS, FY2028 earnings at $3.86 EPS and FY2029 earnings at $6.06 EPS.

VERA has been the topic of several other reports. JPMorgan Chase & Co. decreased their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 4th. Wolfe Research initiated coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 target price for the company. Cantor Fitzgerald lowered their target price on Vera Therapeutics from $107.00 to $100.00 and set an “overweight” rating for the company in a research note on Wednesday, May 7th. Guggenheim increased their target price on Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. Finally, Wedbush reduced their target price on shares of Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $65.00.

Vera Therapeutics Stock Performance

Shares of NASDAQ:VERA traded down $8.65 during trading on Monday, reaching $21.98. The stock had a trading volume of 9,189,503 shares, compared to its average volume of 1,257,062. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The stock has a fifty day simple moving average of $22.39 and a two-hundred day simple moving average of $31.76. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of -8.42 and a beta of 1.13. Vera Therapeutics has a 52 week low of $18.53 and a 52 week high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). During the same quarter last year, the company posted ($0.56) earnings per share. As a group, analysts anticipate that Vera Therapeutics will post -2.89 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vera Therapeutics

Several institutional investors have recently modified their holdings of the business. Barclays PLC increased its position in Vera Therapeutics by 94.1% in the third quarter. Barclays PLC now owns 85,395 shares of the company’s stock worth $3,774,000 after purchasing an additional 41,394 shares during the last quarter. KBC Group NV increased its position in shares of Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock valued at $105,000 after acquiring an additional 1,387 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Vera Therapeutics by 27.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,427 shares of the company’s stock worth $568,000 after acquiring an additional 2,882 shares during the period. Jennison Associates LLC increased its holdings in Vera Therapeutics by 82.0% in the 4th quarter. Jennison Associates LLC now owns 813,861 shares of the company’s stock worth $34,418,000 after acquiring an additional 366,763 shares in the last quarter. Finally, Legato Capital Management LLC boosted its position in shares of Vera Therapeutics by 56.0% during the 4th quarter. Legato Capital Management LLC now owns 13,454 shares of the company’s stock valued at $569,000 after acquiring an additional 4,831 shares during the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.